Essential cookies by default. The browser ID, load-time metrics and error replays only run if you choose "Accept all".
We use essential cookies by default: sign-in, your choice in this banner (supstack-consent) and your language (NEXT_LOCALE). Vercel Web Analytics (cookieless page counts) and Sentry error reports (without replay) run either way. Only if you choose "Accept all" do we also create a browser ID in local storage (it ties your visits together in our site records), record error-replay diagnostics (Sentry: masked DOM snapshots, only when an error fires) and turn on load-time metrics (Vercel Speed Insights) so we can fix slow pages faster. Learn more about cookies
Efinaconazole doesn't have enough studies with structured effect-size data yet to pool a verdict. Browse the studies below for individual findings.
Most evidence is from high-quality meta-analyses and randomised trials published 2013–2026 with a typical study size of 1,655 participants.
Based on 10 studies · 2 meta-analyses · 5 RCTs · 19,470 total participants
Study base
10 studies indexed
By outcome
Every outcome below: Too few graded studies.
Safety profile5 studies
5 studies
Hair & nails3 studies
3 studies
Active research area
4 studies in the last 5 years · Latest meta-analysis: 2020
201320192026
1Meta-AnalysisCited 42×n=12,501 · very large study2020
In plain English: Efinaconazole 10% solution is more effective than vehicle in achieving complete cure (RR 3.54, 95% CI 2.24 to 5.60; 3 studies, 1716 participants) and clinical cure (RR 3.07, 95% CI 2.08 to 4.53; 2 studies, 1655 participants) (both high-quality evidence).
Foley K, et al. · Cochrane Database Syst Rev (2020)
56 studies, 12,501 participants across all topical and device-based treatments for toenail onychomycosis.
Efinaconazole's complete-cure and clinical-cure results are both rated HIGH quality. The same review rates ciclopirox's complete-cure result LOW.
Mycological cure is the weakest of its three efficacy results: RR 2.31 (95% CI 1.08 to 4.94), moderate quality, with a lower bound very close to 1.
In plain English: The primary end point, complete cure, was also significantly greater for efinaconazole (study 1: 17.8% vs 3.3%, study 2: 15.2% vs 5.5%, P < .001).
Elewski BE, et al. · J Am Acad Dermatol (2013)
Two identical multicentre randomised double-blind vehicle-controlled studies, 870 and 785 patients, randomised 3:1, once daily for 48 weeks with 4-week follow-up.
Primary endpoint was complete cure at week 52: 0% clinical involvement AND negative potassium hydroxide examination AND negative culture.
Mycological cure 55.2% and 53.4% against vehicle (P < .001), on the same trials whose complete-cure rates were 17.8% and 15.2%.
3Meta-AnalysisCited 17×2015
In plain English: Fluconazole, efinaconazole, ciclopirox, terbinafine nail solution, and amorolfine treatments were significantly superior to only placebo.
Gupta AK, et al. · J Am Podiatr Med Assoc (2015)
Network meta-analysis, needed because onychomycosis treatments are seldom compared head to head.
12-week continuous oral terbinafine 250 mg was superior to all treatments except itraconazole 400 mg pulse therapy.
On mycological cure the topicals, efinaconazole included, were superior only to placebo and the abstract describes them as equivalent to one another. The Cochrane separation between them is on complete cure, a different endpoint.
4ReviewCited 1×n=1,655 · large study2014
In plain English: The combined results show a 56% mycologic cure rate compared with 17% for vehicle at week 52.
Gupta AK, Elewski BE, et al. · J Am Podiatr Med Assoc (2014)
Pooled report of the two pivotal trials across the United States, Canada and Japan, 1,655 patients.
Mycological cure 56% against 17% on vehicle at week 52.
The abstract states a clinical treatment success figure twice and gives two different numbers, 43% and 47%. Neither is quoted here as the result because the abstract does not resolve which is which.
5RCTCited 2×n=218 · medium study2025
In plain English: At week 52, a significantly greater proportion of older adults (aged 65-71 years) achieved complete cure with efinaconazole than vehicle (13.6% vs. 3.6%; p < 0.05).
Gupta AK, et al. · Mycoses (2025)
POST-HOC pooled analysis of the same two phase 3 studies, restricted to participants aged 65 and over: 162 treated, 56 vehicle.
Complete cure 13.6% against 3.6% (p < 0.05); complete/almost complete cure 19.1% against 5.4% (p = 0.01); mycological cure 59.2% against 12.5% (p < 0.001).
Treatment-related adverse events were 6.0%, similar to the overall study population.
6Review2024
In plain English: Efinaconazole may be a consideration when terbinafine resistance is a concern, due to its different target of action.
Gupta AK, Mann A, Polla Ravi S, Wang T, Cooper EA. · Expert opinion on pharmacotherapy (2024)
In plain English: At week 52, more efinaconazole- vs vehicle-treated participants achieved complete cure (White, 14.7% vs 2.0%; Asian, 27.5% vs 13.0%; Black, 12.9% vs 7.1%).
Elewski BE, et al. · J Drugs Dermatol (2026)
POST-HOC pooled analysis of the two phase 3 trials (NCT01007708, NCT01008033) by self-reported race: White 1,251, Asian 269, Black 98.
Complete cure: White 14.7% vs 2.0%, Asian 27.5% vs 13.0%, Black 12.9% vs 7.1%.
Mycological cure ranged 53.4% to 61.4% with efinaconazole against 10.7% to 30.4% with vehicle.
8RCTCited 6×n=1,655 · large study2018
In plain English: Baseline nail involvement did not appear to predict treatment outcomes.
Gupta AK, et al. · J Drugs Dermatol (2018)
POST-HOC pooled analysis of two identical multicentre randomised double-blind vehicle-controlled studies in 1,655 patients aged 18-70, asking whether baseline severity predicts cure.
Null result, and it is the point of the paper: baseline nail involvement did not appear to predict treatment outcomes.
Of the 237 efinaconazole patients who were clear at week 52, 37% / 24% / 39% had mild / moderate / moderately severe disease at baseline, so cures were not concentrated in the mildest cases.
9Open-LabelCited 10×n=101 · medium study2021
In plain English: Mycological cure (MC) was 60.0% at M12, increasing to 74.2% at M24; effective cure (MC and ≤10% clinical involvement of the target toenail) was 17.8% at M12, rising to 19.4% at M24.
Gupta AK, et al. · Skin Therapy Lett (2021)
101 patients applying efinaconazole to all affected toenails once daily for 18 to 24 months, assessed at months 6, 12, 18 and 24.
The key contrast: over a second year, mycological cure rose 14 points while effective cure rose 1.6. More fungus killed, barely more usable nails.
Application-site reactions in 8 patients (7.9%) were the only drug-related adverse events.
10RCTCited 14×n=30 · small study2019
In plain English: Both efinaconazole and combination with laser were efficacious treatment, but the combination therapy leads to quicker resolution with fewer rate of relapse.
Lim EH, et al. · J Cosmet Laser Ther (2019)
30 subjects randomised to efinaconazole alone or efinaconazole plus six Nd:YAG laser treatments every four weeks, over 48 weeks.
The combination reached mycological cure faster at the 48- and 52-week assessments.
The stated primary endpoint was complete cure at week 52, and the abstract never reports it. What it reports is a secondary mycological finding.